The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Is fluorescein-guided technique able to help in resection of high-grade gliomas?
Open accessAbstract
Object: Fluorescein, a dye that is widely used as a fluorescent tracer, accumulates in cerebral areas where the blood-brain barrier is damaged. This quality makes it an ideal dye for the intraoperative visualization of high-grade gliomas (HGGs). The authors report their experience with a new fluorescein-guided technique for the resection of HGGs using a dedicated filter on the surgical microscope. Methods: The authors initiated a prospective Phase II trial (FLUOGLIO) in September 2011 with the objective of evaluating the safety of fluorescein-guided surgery for HGGs and obtaining preliminary evidence regarding its efficacy for this purpose. To be eligible for participation in the study, a patient had to have suspected HGG amenable to complete resection of the contrast-enhancing area. The present report is based on the analysis of the short- and long-term results in 20 consecutive patients with HGGs (age range 45–74 years), enrolled in the study since September 2011. In all cases fluorescein (5–10 mg/kg) was injected intravenously after intubation. Tumor resection was performed with microsurgical technique and fluorescence visualization by means of BLUE 400 or YELLOW 560 filters on a Pentero microscope. Results: The median preoperative tumor volume was 30.3 cm 3 (range 2.4–87.8 cm 3 ). There were no adverse reactions related to fluorescein administration. Complete removal of contrast-enhanced tumor was achieved in 80% of the patients. The median duration of follow-up was 10 months. The 6-months progression-free survival rate was 71.4% and the median survival was 11 months. Conclusions: Analysis of these 20 cases suggested that fluorescein-guided technique with a dedicated filter on the surgical microscope is safe and allows a high rate of complete resection of contrast-enhanced tumor as determined on early postoperative MRI. Clinical trial registration no.: 2011-002527-18 (EudraCT).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
Shinoda, J., Yano, H., Yoshimura, S.-I., Okumura, A., Kaku, Y., Iwama, T., & Sakai, N. (2003) · Journal of Neurosurgery · doi:10.3171/jns.2003.99.3.0597 · Cited by 249
Cited by
Nagaya, T., Nakamura, Y. A., Choyke, P. L., & Kobayashi, H. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00314 · Cited by 398
Schupper, A. J., Baron, R. B., Cheung, W., Rodriguez, J., Kalkanis, S. N., Chohan, M. O., Andersen, B. J., Chamoun, R., Nahed, B. V., Zacharia, B. E., et al. (2022) · Journal of Neurosurgery · doi:10.3171/2021.5.jns21310 · Cited by 59
Metadata
- Authors
- Acerbi, F., Broggi, M., Eoli, M., Anghileri, E., Cavallo, C., Boffano, C., Cordella, R., Cuppini, L., Pollo, B., Schiariti, M., Visintini, S., Orsi, C., La Corte, E., Broggi, G., & Ferroli, P.
- Venue
- Neurosurgical Focus
- Published
- 2014-02
- Volume
- 36
- Issue
- 2
- Pages
- E5
- ISSN
- 1092-0684 (ISSN-L)
- OpenAlex
- W2064237424
- Cited by
- 170
- References
- 3
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is fluorescein-guided technique able to help in resection of high-grade gliomas? https://app.cochat.ai/papers/10.3171/2013.11.focus13487
- The paper
- Acerbi, F., Broggi, M., Eoli, M., Anghileri, E., Cavallo, C., Boffano, C., Cordella, R., Cuppini, L., Pollo, B., Schiariti, M., Visintini, S., Orsi, C., La Corte, E., Broggi, G., & Ferroli, P. (2014). Is fluorescein-guided technique able to help in resection of high-grade gliomas? Neurosurgical Focus. https://doi.org/10.3171/2013.11.focus13487
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.